Novartis Rejoins Protein Degradation Space with US$1.3 B Dunad Deal
By Lucy Haggerty
Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)
Published: 8 Nov-2021
DOI: 10.3833/pdr.v2021.i11.2644 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Jump starting its presence in protein degradation therapies, Novartis has entered into a strategic research collaboration with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for up to four undisclosed targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS